Although the NAIP5/NLRC4 inflammasome-mediated IL-1β secretion in response to the injection of flagellin-modified tumor cells, it is unclear whether the involvement of this cytokine was necessary for the success of this immunotherapy. This evidence concerns the gene NLRC4 and neoplasm.